Formoterol porous particle

Drug Profile

Formoterol porous particle

Alternative Names: FF MDI; PT-005

Latest Information Update: 20 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pearl Therapeutics
  • Class Antiasthmatics; Bronchodilators; Ethanolamines; Small molecules
  • Mechanism of Action Beta 2 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Chronic obstructive pulmonary disease

Most Recent Events

  • 31 Aug 2017 Pearl Therapeutics completes a phase III trial in Chronic obstructive pulmonary disease in Hungary, Poland, Czech Republic, Germany, United Kingdom, USA (Inhalation) (NCT02343458) (EudraCT2014-004712-10)
  • 30 Sep 2016 Discontinued - Phase-III for Chronic obstructive pulmonary disease in Australia, New Zealand, USA (Inhalation)
  • 01 Mar 2015 Pearl Therapeutics completes a phase II trial for Chronic obstructive pulmonary disease in USA (NCT02196077)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top